GlassScriptPhysician profile
Casey M Turek
NPI 1003480534
$11,294.01
in general payments reported to CMS, 2019-2025
30 companies · $5,015 in 2025
The $5,015 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $1,194 · 2023: $2,089 · 2024: $2,770 · 2025: $5,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,476 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,476.18 |
| Education | $398.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,652.97 | 2021-2025 | Opzelura, Opzelura |
| Amgen INC. | $1,149.96 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $963.62 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $853.01 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Dermavant Sciences, INC. | $737.29 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $662.76 | 2024-2025 | Zoryve |
| Pfizer INC. | $613.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $570.54 | 2021-2025 | |
| Janssen Biotech, INC. | $508.19 | 2023-2025 | Tremfya |
| Genzyme Corporation | $474.55 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $407.84 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $359.31 | 2024-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $333.73 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $281.85 | 2024-2025 | Bimzelx |
| Organogenesis INC. | $276.62 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $249.28 | 2023-2025 | Adbry, Anzupgo |
| Botanix Sb INC | $229.09 | 2025 | Sofdra |
| Organon LLC | $221.21 | 2025 | Vtama |
| Lilly USA, LLC | $156.63 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Revance Therapeutics, INC. | $130.24 | 2025 | Daxxify |
| Kerecis Limited | $96.22 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $86.41 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.07 | 2024-2025 | Jublia, Cabtreo, Siliq |
| Smith+Nephew, INC. | $28.56 | 2023 | Grafix Pl |
| Lnhc, INC | $25.85 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $24.94 | 2025 | Ycanth |
| Tempus Ai, INC | $18.02 | 2024 | Merlin Test |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.74 | 2023 | Spevigo |
| Biofrontera INC. | $14.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Turek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.